Novo Nordisk A/S
SWB:NOVA

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
SWB:NOVA
Watchlist
Price: 40.8 EUR 0.62%
Market Cap: 87.8B EUR

EV/EBIT
Enterprise Value to EBIT

11.3
Current
25.6
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
11.3
=
Enterprise Value
1.5T DKK
/
EBIT
132.7B DKK
All Countries
Close
Market Cap EV/EBIT
DK
Novo Nordisk A/S
SWB:NOVA
1.4T EUR 11.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 21.1
CH
Roche Holding AG
SIX:ROG
260.9B CHF 13.8
UK
AstraZeneca PLC
LSE:AZN
213.2B GBP 159.7
CH
Novartis AG
SIX:NOVN
209.9B CHF 15.1
US
Merck & Co Inc
NYSE:MRK
260.5B USD 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 830.4
US
Pfizer Inc
NYSE:PFE
143.3B USD 10.2
FR
Sanofi SA
PAR:SAN
99.6B EUR 6.6
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
SWB:NOVA
Average EV/EBIT: 1 711.1
11.3
1%
11.3
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.5
8%
1.4
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
11.3
2-Years Forward
EV/EBIT
11
3-Years Forward
EV/EBIT
10.3